Acquired Coagulation Inhibitors in the Non-Congenital Factor Deficient Population: Clinical Manifestations and Management
Although antibodies to coagulation proteins occur frequently in the patients with congenital deficiencies of procoagulant proteins, their appearance in the non-hemophilic population is rare  Offsetting the rarity of these inhibitors is the severity of the clinical consequences of what has been termed acquired hemophilia; when these inhibitors do appear, they produce recurrent, devastating hemorrhage.
Unable to display preview. Download preview PDF.
- 4.Biggs R (1976) Human blood coagulation, haemostasis and thrombosis. Bladenwell, Oxford, pp 702–704Google Scholar
- 5.Kasper C (1975) A more uniform measurement of factor VIII inhibitor. Thromb Diath Haemorrh 34: 869–872Google Scholar
- 11.Ludlam CA, Morrison AE, Kessler C (1994) Treatment of acquired hemophilia. Semin Hematol(Suppl) 31: 16–19Google Scholar
- 12.Allain JP, Gaillandre A, Frommel D (1981) Acquired hemophilia: Functional study of antibodies to Factor VIII. Thromb Haemost 45: 285–289Google Scholar
- 14.Hoyer LW, Gawryl MS, de la Fuente B (1984) Immunochemical characterization of Factor VIII inhibitors. In: Hoyer Lw (ed) Factor VIII inhibitors. Liss, New York, pp 73–85Google Scholar